Intercept Pharmaceuticals Inc (ICPT)
20.38
-0.46 -2.21%
NASDAQ
Jun 22, 12:58
USD
Intercept Pharmaceuticals Gross Profit Margin (Quarterly):
99.01% for March 31, 2021View 4,000+ financial data types
Browse...
View Full Chart
Gross Profit Margin (Quarterly) Chart
Export Data
Save Image
Print Image
For advanced charting, view our full-featured
Fundamental Chart
Historical Gross Profit Margin (Quarterly) Data
View and export this data going back to 2017.
Start your Free Trial
Export Data
Date Range:
| Data for this Date Range | |
|---|---|
| March 31, 2021 | 99.01% |
| Dec. 31, 2020 | 99.08% |
| Sept. 30, 2020 | 97.70% |
| June 30, 2020 | 97.57% |
| March 31, 2020 | 98.83% |
| Dec. 31, 2019 | 96.54% |
| Sept. 30, 2019 | 99.21% |
| June 30, 2019 | 98.98% |
| March 31, 2019 | 98.90% |
| Dec. 31, 2018 | 98.11% |
| Sept. 30, 2018 | 98.90% |
| June 30, 2018 | 98.36% |
| March 31, 2018 | 99.22% |
| Dec. 31, 2017 | 97.82% |
| Sept. 30, 2017 | 99.58% |
| June 30, 2017 | 99.10% |
| March 31, 2017 | 99.54% |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
Advertisement
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Benchmarks
| Insmed Inc | 75.52% |
| Cassava Sciences Inc | -- |
| Regeneron Pharmaceuticals Inc | 87.82% |
Gross Profit Margin (Quarterly) Range, Past 5 Years
| Minimum | 96.54% | Dec 2019 |
| Maximum | 99.58% | Sep 2017 |
| Average | 98.61% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -37.15% |
| Return on Invested Capital | -51.55% |
| Profit Margin (Quarterly) | -49.50% |
| Operating Margin (Quarterly) | -35.74% |
| Return on Net Operating Assets | -199.9% |
News
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
Globe Newswire 06/21 08:00 ET
Globe Newswire 06/21 08:00 ET
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
Globe Newswire 06/15 08:00 ET
Globe Newswire 06/15 08:00 ET
Asensus Surgical to join Russell Microcap Index, while Sorrento Therapeutics to see deletion
SA Breaking News 06/14 15:29 ET
SA Breaking News 06/14 15:29 ET
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
Globe Newswire 06/09 08:00 ET
Globe Newswire 06/09 08:00 ET
Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information
Globe Newswire 05/26 16:30 ET
Globe Newswire 05/26 16:30 ET
B. Riley Downgrades Intercept Pharmaceuticals to Neutral from Buy, Adjusts Price Target to $18 from $65
MT Newswires 05/25 09:44 ET
MT Newswires 05/25 09:44 ET
NGM Biopharma price target cut by more than half at Raymond James after NASH setback
SA Breaking News 05/24 13:51 ET
SA Breaking News 05/24 13:51 ET
Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Globe Newswire 05/12 08:00 ET
Globe Newswire 05/12 08:00 ET
Advertisement
